Melatonin and breast cancer: a mathematical modeling approach in blind women

Year 2025, Volume: 3 Issue: 2, 164 - 191, 31.10.2025

Aytekin Enver , Fatma Ayaz

https://doi.org/10.59292/bulletinbiomath.1783080

Abstract

Melatonin, a hormone secreted by the pineal gland, regulates circadian rhythms and exhibits strong anticancer potential through its antioxidant, immunomodulatory, and hormonal effects. This study develops a novel reaction–diffusion mathematical model to describe multiscale interactions among melatonin, breast cancer cells, and immune responses, emphasizing blind women who sustain high melatonin levels due to a lack of light perception. The model uniquely integrates hormonal, oxidative, and immune processes within a unified spatio-temporal framework, enabling joint analysis of tumor proliferation, melatonin-induced inhibition, immune cytotoxicity, and fibroblast-mediated tumor stimulation. Epidemiological evidence indicates that blind women show a markedly lower incidence of hormone-dependent cancers, attributed to continuous melatonin activity. Numerical simulations demonstrate that elevated melatonin concentrations suppress tumor growth, strengthen immune activity, and reduce fibroblast-driven promotion. Moreover, stress-related melatonin depletion is shown to disrupt tumor–immune balance, supporting the hypothesis that circadian rhythm disturbance accelerates tumor progression. The findings offer mechanistic insight into melatonin’s dual preventive and therapeutic roles and establish a quantitative link between biochemical regulation and tumor dynamics. By coupling biological data with mathematical rigor, the proposed framework advances mathematical oncology by uniting circadian biology, immunology, and tumor modeling within a single analytical structure.

Keywords

Melatonin , Breast Cancer , Mathematical Modeling , Reaction–Diffusion , Blind Women

References

• [1] World Health Organization, International Agency for Research on Cancer (IARC). [https://iarc.who.int/], [Accessed: 12/09/2025]
• [2] World Health Organization, International Agency for Research on Cancer (IARC), Cancer Over Time: Cohort data - Populations=792, Sexes=2. GLOBOCAN, (2025). [https://gco.iarc.fr/overtime/en/dataviz/cohorts?populations=792&sexes=2], [Accessed: 12/09/2025]
• [3] Yi, Y.J., Tang, H., Pi, P.L., Zhang, H.W., Du, S.Y., Ge, W.Y. et al. Melatonin in cancer biology: Pathways, derivatives, and the promise of targeted delivery. Drug Metabolism Reviews, 56(1), 62-79, (2024).
• [4] Bayrakçeken, E., Yaralı, S. and Alkan, Ö. Identify risk factors affecting participation of Turkish women in mammography screening for breast cancer prevention. Breast Cancer Research and Treatment, 205, 487-495, (2024).
• [5] Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I. and Jemal, A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 74(3), 229-263, (2024).
• [6] Joshi, H., Yavuz, M. and Stamova, I. Analysis of the disturbance effect in intracellular calcium dynamic on fibroblast cells with an exponential kernel law. Bulletin of Biomathematics, 1(1), 24-39, (2023).
• [7] Duffy, S.W., Vulkan, D., Cuckle, H., Parmar, D., Sheikh, S., Smith, R.A. et al. Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial. The Lancet Oncology, 21(9), 1165-1172, (2020).
• [8] Calvo, J.R. and Maldonado, M.D. Immunoregulatory properties of melatonin in the humoral immune system: A narrative review. Immunology Letters, 269, 106901, (2024).
• [9] Koul, A.M., Shafi, T., Anwar, I., Banday, M., Iqra, S., Gull, A. et al. Melatonin and immune modulation. In Melatonin: A Ubiquitous Pleiotropic Molecule (pp. 163-185). Elsevier, New York, USA: Academic Press, (2024).
• [10] Motehaver, A.N., Sheida, F., Javadinia, S.A., Behzadi, B., Afshar, S., Khezrian, A. et al. Melatonin and breast cancer: A review article. Chonnam Medical Journal, 61(2), 63-74, (2025).
• [11] Yu, Z.Y., Peng, R.Y., Cheng, N., Wang, R.T., Nan, M.D., Milazzo, S. et al. Melatonin in cancer treatment. Cochrane Database of Systematic Reviews, 4, CD010145, (2025).
• [12] de Pillis, L.G., Radunskaya, A.E. and Wiseman, C.L. A validated mathematical model of cell-mediated immune response to tumor growth. Cancer Research, 65(17), 7950-7958, (2005).
• [13] Ekmekcioglu, C. Melatonin receptors in humans: Biological role and clinical relevance. Biomedicine & Pharmacotherapy, 60(3), 97-108, (2006).
• [14] Pukkala, E., Ojamo, M., Rudanko, S.L., Stevens, R.G. and Verkasalo, P.K. Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment. Cancer Causes & Control, 17, 573–576, (2006).
• [15] Minella, C., Coliat, P., Amé, S., Neuberger, K., Stora, A., Mathelin, C. and Reix, N. Protective role of melatonin in breast cancer: what we can learn from women with blindness. Cancer Causes & Control, 33, 1-13, (2022).
• [16] Ucar, S., Koca, I., Özdemir, N. and Inci, T. A stochastic approach to tumor modeling incorporating macrophages. Bulletin of Biomathematics, 2(2), 162-181, (2024).
• [17] Lee, J. and Kim, E. Ordinary differential equation model of cancer-associated fibroblast heterogeneity predicts treatment outcomes. Systems Biology and Applications, 11, 96, (2025).
• [18] Andasari, V., Gerisch, A., South, A.P. and Chaplain, M.A. J. Mathematical modeling of cancer cell invasion of tissue: Development of an in silico organotypic assay. bioRxiv, 1-19, (2025).
• [19] Roma-Rodrigues, C., Mendes, R., Baptista, P.V. and Fernandes, A.R. Targeting tumor microenvironment for cancer therapy. International Journal of Molecular Sciences, 20(4), 840, (2019).
• [20] Carrillo-Vico, A., Guerrero, J.M., Lardone, P.J. and Reiter, R.J. A review of the multiple actions of melatonin on the immune system. Endocrine, 27, 189-200, (2005).
• [21] Kubatka, P., Zubor, P., Busselberg, D., Kwon, T.K., Adamek, M., Petrovic, D. et al. Melatonin and breast cancer: Evidences from preclinical and human studies. Critical Reviews in Oncology/Hematology, 122, 133-143, (2018).
• [22] Storey, K.M., Lawler, S.E. and Jackson, T.L. Modeling oncolytic viral therapy, immune checkpoint inhibition, and the complex dynamics of innate and adaptive immunity in glioblastoma treatment. Frontiers in Physiology, 11, 151, (2020).
• [23] Eyduran, Ş.P., Çolak, A.M., Berk, S.K., Sakalda¸s, M., Şen, F. and Gundogdu, M. Reducing respiration rate and increasing chemical stability of mulberry fruits by using postharvest putrescine and melatonin. BMC Plant Biology, 25, 431, (2025).
• [24] Talib, W.H., Alsayed, A.R., Abuawad, A., Daoud, S. and Mahmod, A.I. Melatonin in cancer treatment: current knowledge and future opportunities. Molecules, 26(9), 2506, (2021).
• [25] Xu, C., Zhou, J., Li, F. and Wang, H. Melatonin suppression in tumor-bearing models: Mechanisms linking circadian disruption, oxidative stress, and immune dysfunction. Frontiers in Endocrinology, 13, 890457, (2022).
• [26] Giangreco, G., Rullan, A., Naito, Y., Biswas, D., Liu, Y.H., Hooper, S. et al. Cancer cell–Fibroblast crosstalk via HB-EGF, EGFR, and MAPK signaling promotes the expression of macrophage chemo-attractants in squamous cell carcinoma. IScience, 27(9), 110635, (2024).
• [27] Enver, A. and Ayaz, F. Mathematical modeling of stress-induced type 2 diabetes and atherosclerosis: Numerical methods and stability analysis. Results in Nonlinear Analysis, 8(1), 204-225, (2025).
• [28] Enver, A., Ayaz, F. and Yalçınkaya, D.E. A multiscale coupled reaction-diffusion model of amyloid-beta and tau pathology in Alzheimer’s disease. Journal of Nonlinear Modeling and Analysis, 7(5), 1940-1964, (2025).